(2-溴-4-甲基-噻唑-5-基)-甲醇 | 933782-03-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: (2-溴-4-甲基-噻唑-5-基)-甲醇
• 英文名称: (2-bromo-4-methylthiazol-5-yl)methanol
• 英文别名: (2-bromo-4-methyl-1,3-thiazol-5-yl)methanol
• CAS: 933782-03-7
• 化学式: C₅H₆BrNOS
• 分子量: 208.079
• InChiKey: XLVPVZKGRKXLIA-UHFFFAOYSA-N

物化性质

• 沸点：
  303.3±27.0 °C(Predicted)
• 密度：
  1.757±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  61.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  (2-溴-4-甲基-噻唑-5-基)-甲醇 在 氯化亚砜 、 sodium carbonate 、 caesium carbonate 、 三氟乙酸 作用下， 以 乙二醇二甲醚 、 二氯甲烷 、 氯仿 、 乙腈 为溶剂， 反应 22.5h， 生成 2-(4-(((2-(4-fluorophenyl)-4-methylthiazol-5-yl)methyl)thio)-2-methylphenoxy)acetic acid
  参考文献：
  名称：

  Parallel Chemistry Approach to Identify Novel Nuclear Receptor Ligands Based on the GW0742 Scaffold

  摘要：

  We describe the parallel synthesis of novel analogs of GW0742, a peroxisome proliferator-activated receptor delta (PPAR delta) agonist For that purpose, modified reaction conditions were applied, such as a solid-phase palladium-catalyzed Suzuki coupling. In addition, tetrazole-based compounds were generated as a bioisostere for carboxylic acid-containing ligand GW0742. The new compounds were investigated for their ability to activate PPAR delta mediated transcription and their cross-reactivity with the vitamin D receptor (VDR), another member of the nuclear receptor superfamily. We identified many potent PPAR delta agonists that were less toxic than GW0742, where similar to 65 of the compounds synthesized exhibited partial PPAR delta activity (23-98%) with EC50 values ranging from 0.007-18.2 mu M. Some ligands, such as compound 32, were more potent inhibitors of VDR-mediated transcription with significantly reduced PPAR delta activity than GW0742, however, none of the ligands were completely selective for VDR inhibition over PPAR delta activation of transcription.

  DOI：

  10.1021/acscombsci.7b00066
• 作为产物：
  描述：

  2-溴-4-甲基-1,3-噻唑-5-甲酸乙酯 在 sodium tetrahydroborate 作用下， 以 乙醇 、 水 、 乙酸乙酯 为溶剂， 反应 12.0h， 生成 (2-溴-4-甲基-噻唑-5-基)-甲醇
  参考文献：
  名称：

  Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals

  摘要：

  本发明的创新化合物由苯基和吡啶基-1,2,4-噁二唑酮衍生物以及它们的生理上可接受的盐和功能衍生物组成，已被证明具有过氧化物酶体增殖激活受体（PPARδ）激动剂活性。本发明的化合物由以下公式组成：其中取代基R1-R5和R7-R10在此定义。这些化合物在哺乳动物的脂质和碳水化合物代谢的调节和调控方面具有治疗效果，因此适用于治疗糖尿病、动脉粥样硬化、心血管疾病等疾病。

  公开号：

  US20080261979A1

文献信息

• [EN] NOVEL OXAZOLE AND THIAZOLE COMPOUNDS AS Β-CATENIN MODULATORS AND USES THEREOF<br/>[FR] NOUVEAUX COMPOSÉS OXAZOLES ET THIAZOLES POUVANT ÊTRE UTILISÉS COMME MODULATEURS DE LA Β-CATÉNINE ET LEURS UTILISATIONS
  申请人：UNIV NEW YORK

  公开号：WO2017152032A1

  公开（公告）日：2017-09-08

  Heterocyclic compounds according to formula I: wherein A, B, Y, and Cy are as described herein, are provided as inhibitors of the Wnt pathway that specifically target the activity of the stabilized pool of B-cat. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, cancer, and other conditions related to Wnt pathway dysfunction, including various cancers and pulmonary fibrosis.

  根据公式I，提供了异环化合物，其中A、B、Y和Cy如本文所述，作为Wnt途径的抑制剂，专门靶向稳定的B-cat池的活性。这些化合物可以制备为药物组合物，并可用于预防和治疗包括人类在内的哺乳动物的各种疾病，例如癌症以及与Wnt途径功能障碍相关的其他疾病，包括各种癌症和肺纤维化。
• Enantioselective Synthesis of Oxetanes Bearing All-Carbon Quaternary Stereocenters via Iridium-Catalyzed C−C Bond-Forming Transfer Hydrogenation
  作者：Yi-An Guo、Wonchul Lee、Michael J. Krische

  DOI：10.1002/chem.201606046

  日期：2017.2.21

  Oxetanes bearing all‐carbon quaternary stereocenters are readily prepared through the iridium‐catalyzed anti‐diastereo‐ and enantioselective C−C coupling of primary alcohols and isoprene oxide. Based on this methodology, an oxetane containing analogue of haloperidol was prepared. A related azetidine formation is also described.

  氧杂环丁烷轴承全碳季立体通过铱催化的容易地制备抗-diastereo-和不对称C-C伯醇和异戊二烯氧化物的耦合。基于该方法，制备了含氧杂环丁烷的氟哌啶醇类似物。还描述了相关的氮杂环丁烷形成。
• HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES
  申请人：Bunnage Mark Edward

  公开号：US20130196952A1

  公开（公告）日：2013-08-01

  The invention relates to compounds of Formula (1) and to processes for the preparation of intermediates used in the preparation of compositions containing and the uses of such derivatives. The compounds according to the present invention are useful in numerous diseases in which ALK protein is involved or in which inhibition of ALK activity may induce benefit, especially for the treatment of cancer mediated by a mutated EML4-ALK fusion protein.

  本发明涉及式（1）的化合物，以及用于制备含有这些衍生物的组合物的中间体的制备过程和使用。根据本发明的化合物在许多与ALK蛋白有关或抑制ALK活性可能产生益处的疾病中非常有用，特别是用于治疗由突变的EML4-ALK融合蛋白介导的癌症。
• Alkoxy-substituted 2-aminopyridines as ALK inhibitors
  申请人：Bunnage Mark Edward

  公开号：US08916593B2

  公开（公告）日：2014-12-23

  The invention relates to compounds of Formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases in which ALK protein is involved or in which inhibition of ALK activity may induce benefit, especially for the treatment of cancer mediated by a mutated EML4-ALK fusion protein.

  本发明涉及式（1）的化合物以及制备、制备中间体、含有和使用这些衍生物的组合物的过程。根据本发明的化合物在许多涉及ALK蛋白质或抑制ALK活性可能产生益处的疾病中有用，特别是用于治疗由突变的EML4-ALK融合蛋白介导的癌症。
• Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and methods for their use as pharmaceuticals
  申请人：Sanofi-Aventis

  公开号：US07709481B2

  公开（公告）日：2010-05-04

  The inventive compounds of the present invention are comprised of phenyl and pyridinyl-1,2,4-oxadiazolone derivatives and their physiologically acceptable salts and functional derivatives that are shown to provide peroxisome proliferator activator receptor (PPARdelta) agonist activity. The compounds of the present invention are comprised of the formula: wherein the substituents R1-R5 and R7-R10 are defined herein. The compounds are therapeutically effective in the regulation and modulation of lipid and carbohydrate metabolism in mammals and are thus suitable for the treatment of diseases such as type-2 diabetes, atherosclerosis, cardiovascular disorders and the like.

  本发明的创新化合物包括苯基和吡啶基-1,2,4-噁二唑酮衍生物及其生理上可接受的盐和功能衍生物，这些化合物被证明具有过氧化物酶体增殖激活受体（PPARδ）激动剂活性。本发明的化合物由以下公式组成：其中取代基R1-R5和R7-R10在此定义。这些化合物在哺乳动物的脂质和碳水化合物代谢的调节和调节中具有治疗效果，因此适用于治疗2型糖尿病、动脉粥样硬化、心血管疾病等疾病。